NASDAQ · NXTC
Healthcare · Biotechnology
$7.82
Down-$0.02 (-0.26%)
Updated Sep 6, 2026, 11:17 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NXTC closed at $7.82 after 20 trading sessions, up 14.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $7.79 | $8.23 | $7.5701 | $7.82 | 60.63K |
| Sep 3, 2026 | $7.48 | $8.30 | $7.1061 | $7.84 | 161.56K |
| Sep 2, 2026 | $6.70 | $7.44 | $6.475 | $7.35 | 112.64K |
| Sep 1, 2026 | $6.38 | $6.86 | $6.16 | $6.80 | 112.9K |
| Aug 31, 2026 | $6.13 | $6.5799 | $6.0776 | $6.39 | 54.89K |
| Aug 28, 2026 | $5.98 | $6.20 | $5.9301 | $6.09 | 60.9K |
| Aug 27, 2026 | $5.95 | $6.34 | $5.932 | $6.035 | 73.44K |
| Aug 26, 2026 | $5.85 | $6.19 | $5.60 | $5.83 | 92.18K |
| Aug 25, 2026 | $5.93 | $6.7594 | $5.84 | $5.91 | 160.42K |
| Aug 24, 2026 | $6.20 | $6.6286 | $5.69 | $5.89 | 121.65K |
| Aug 21, 2026 | $6.19 | $6.58 | $6.19 | $6.29 | 36.97K |
| Aug 20, 2026 | $6.55 | $6.725 | $6.00 | $6.25 | 86.36K |
| Aug 19, 2026 | $6.72 | $7.26 | $6.60 | $6.78 | 157.05K |
| Aug 18, 2026 | $7.47 | $7.80 | $6.51 | $6.65 | 257.33K |
| Aug 17, 2026 | $8.17 | $8.285 | $7.58 | $7.71 | 184.43K |
| Aug 14, 2026 | $8.13 | $8.39 | $7.54 | $8.21 | 262K |
| Aug 13, 2026 | $8.24 | $8.66 | $7.83 | $8.28 | 286.1K |
| Aug 12, 2026 | $6.75 | $8.72 | $6.60 | $8.17 | 493.35K |
| Aug 11, 2026 | $6.52 | $6.92 | $6.46 | $6.73 | 181.44K |
| Aug 10, 2026 | $6.16 | $7.1672 | $5.91 | $6.84 | 1.39M |
The latest Smart Investors Daily articles mentioning NXTC.
NXTC research
Company profile and research snapshot.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Nov 7, 2025 | Ladenburg Thalmann | Buy | — |
| Jul 15, 2025 | Piper Sandler | Overweight | — |
| Jul 1, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals (NASDAQ:AMLX)
Benzinga · Aug 6, 2026
NextCure (NASDAQ:NXTC) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.94) by 45.08 percent. This is a 75.2 percent increase over losses of $(11.29) per share from the
Benzinga · Jul 14, 2026
NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.
Benzinga · Jul 14, 2026
Stocks mixed, Dow falls over 100 points. Nasdaq up 0.88%, S&P up 0.32%. Tech shares surge 1.2%, healthcare falls 1.9%. Headline CPI drops, core CPI flat.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NXTC.
